Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies

American Journal of Transplantation

Volumn 13, Issue 2, 2013, Pages 485-492

  De Kort, H ^a   Willicombe, M ^a   Brookes, P ^a   Dominy, K M ^a   Santos Nunez, E ^a   Galliford, J W ^a   Chan, K ^a   Taube, D ^a   McLean, A G ^a   Cook, H T ^a   Roufosse, C ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Antibody mediated rejection; C4d; donor specific antibodies; histopathology; microcirculation inflammation; renal transplantation

Indexed keywords

ALEMTUZUMAB; ANTIBODY; COMPLEMENT COMPONENT C4D; DACLIZUMAB; DE NOVO DONOR SPECIFIC ANTIBODY; ECULIZUMAB; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; CAPILLARITIS; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLOMERULITIS; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM SURVIVAL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; MICROCIRCULATION INFLAMMATION; NEPHRITIS; PERITUBULAR CAPILLARITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPLENIAL CORTEX; SCORING SYSTEM; SURGICAL RISK;

ADULT; ANTIBODIES; BIOPSY; COMPLEMENT C4B; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MICROCIRCULATION; MIDDLE AGED; MODELS, STATISTICAL; PEPTIDE FRAGMENTS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS;

EID: 84873097671     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04325.x     Document Type: Article

References (26)

1. Haas M., The significance of C4d staining with minimal histologic abnormalities. Curr Opin Organ Transplant 2010; 15: 21-27.
2. Haririan A, Kiangkitiwan B, Kukuruga D, et al. The impact of C4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. Am J Transplant 2009; 9: 2758-2767.
3. Worthington JE, McEwen A, McWilliam LJ, Picton ML, Martin S., Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007; 83: 398-403.
4. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
5. Haas M., Pathologic features of antibody-mediated rejection in renal allografts: An expanding spectrum. Curr Opin Nephrol Hypertens 2012; 21: 264-271.
6. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF., Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
7. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56-65.
8. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
9. Terasaki PI., Humoral theory of transplantation. Am J Transplant 2003; 3: 665-673.
10. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804-2812.
11. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific hla antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
12. Willicombe M, Brookes P, Santos-Nunez E, et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2011; 11: 470-477.
13. Solez K, Colvin RB, Racusen LC, et al. Banff '07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
14. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
15. Zhang Q, Liang LW, Gjertson DW, et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005; 79: 591-598.
16. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-658.
17. Mauiyyedi S, Pelle PD, Saidman SL, et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582.
18. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of hla antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864-871.
19. Terasaki PI, Ozawa M., Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 2004; 4: 438-443.
20. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
21. Everly MJ, Rebellato L, Ozawa M, et al. Epidemiology of de novo donor specific anti-hla antibodies in a consecutive series of "low-risk" renal transplant subjects with 5-10 years follow-up. ATC Congress 2012 Abstracts. Am J Transplant 2012; 12 Suppl S3: 122.
22. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC., Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103-1109.
23. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting Report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-70.
24. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-70.
25. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-79.
26. Zhang Q, Reed EF,. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol 2010; 22: 682-8.